Sometimes in biotech, the biggest news isn't about a clinical trial result or a drug approval. It's about a person leaving a job. That's what happened Monday when shares of uniQure N.V. (QURE) shot up more than 30% in premarket trading. The catalyst? News that Dr. Vinay Prasad, the head of the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), is stepping down at the end of April.
FDA Commissioner Marty Makary confirmed the departure on Friday. For investors in uniQure and a few other biotech names, this wasn't just personnel news—it was a potential sea change. CBER is the division that reviews a wide array of complex treatments, including gene therapies, cancer drugs, and vaccines. And under Prasad, it had developed a reputation for being, let's say, particularly rigorous.
His tenure was a rollercoaster marked by several high-profile and controversial decisions. He was initially named director in May 2025, stepped down briefly at the end of July, and was then rehired in August 2025. During his time, he took a firm stance on the evidence required for drug approvals, which didn't always sit well with drugmakers or patient advocates.
For uniQure, the friction was very public and very specific. The company has been developing a gene therapy called AMT-130 for Huntington's disease, a rare and devastating neurodegenerative disorder. Recently, the FDA, under Prasad's CBER, rejected the company's application. The agency advised against using data from an ongoing Phase 1/2 study as the primary evidence and recommended that uniQure conduct a new, prospective, randomized, double-blind, and sham surgery-controlled study.
That's a big ask. The therapy requires brain surgery, and finding patients with a rare, debilitating disease who are willing to undergo that procedure knowing they might get a placebo is a monumental challenge. Last week, an FDA official defended the call for this additional study, but the debate was already raging.
It's a classic regulatory dilemma. On one side, you have the gold standard of medical evidence: the placebo-controlled trial. On the other, you have the reality of rare diseases, where patient populations are tiny and the unmet need is enormous. The FDA itself had previously signaled flexibility. In 2024, the agency said uniQure could still pursue an accelerated approval without a placebo control, acknowledging the enrollment challenges. Commissioner Makary reiterated this philosophy to CNBC, stating, "We [the FDA] do not believe that you need to use a randomized controlled trial [RCT] model for all rare diseases. We believe in regulatory flexibility."
Prasad's stance, however, appeared to lean harder toward the traditional RCT model. He had also publicly criticized the FDA's decision to approve Sarepta Therapeutics Inc.'s (SRPT) Duchenne muscular dystrophy drug Elevidys, arguing the evidence was thin. His division also initially refused to consider a flu shot application from Moderna Inc. (MRNA) before later reversing course.
So, when The Wall Street Journal first reported Prasad's impending exit, the market reacted instantly. According to market data, uniQure shares jumped as much as 70% in post-market trading after the news broke. The stock had already climbed nearly 34% on Friday to close at $14.27, and the momentum continued Monday with shares hitting $18.75 in premarket activity—a 31.39% surge.
A Bloomberg report directly linked the stock move to the company's "public dispute" with Prasad's division over the requirements for its Huntington's therapy. In essence, investors are betting that with Prasad gone, the path to approval for AMT-130 might get a little easier, or at least be re-evaluated under different leadership. It's a stark reminder of how much influence a single regulator's philosophy can have on a company's valuation and the hopes of patients waiting for new treatments.
